Evidence map›Paper›PMID 38271554›Full record

SynthesisAnnals of medicine2024

Association of non-selective β blockers with the development of renal dysfunction in liver cirrhosis: a systematic review and meta-analysis.

Xiangbo Xu, Fangbo Gao, Ting Wang, Zuyao Yang, Qingchun Zhao, Xingshun Qi

Open access · goldAbstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in Annals of medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 3 countries.

Xiangbo XuDepartment of Clinical Pharmacy, Shenyang Pharmaceutical University, Shenyang, China.
Fangbo GaoDepartment of Clinical Pharmacy, Shenyang Pharmaceutical University, Shenyang, China.
Ting WangDepartment of Clinical Pharmacy, Shenyang Pharmaceutical University, Shenyang, China.
Zuyao YangDivision of Epidemiology, The Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong, China.
Qingchun ZhaoDepartment of Clinical Pharmacy, Shenyang Pharmaceutical University, Shenyang, China.
Xingshun QiDepartment of Clinical Pharmacy, Shenyang Pharmaceutical University, Shenyang, China.
Shenyang Pharmaceutical University · CNChinese University of Hong Kong · HK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND &

aimsNon-selective β blockers (NSBBs) may negatively influence renal function through decreasing heart rate and cardiac output. This study aimed to systematically investigate their association.

methodsPubMed, EMBASE, and Cochrane library databases were searched to identify all relevant studies evaluating the association of NSBBs with renal dysfunction in cirrhotic patients. Unadjusted and adjusted data were separately extracted. Odds ratios (ORs) and hazard ratios (HRs) were pooled. Subgroup meta-analyses were performed according to the proportions of ascites and Child-Pugh class B/C and the mean model for end-stage liver disease (MELD) score. Quality of evidence was assessed using the Grading of Recommendations Assessment, Development, and Evaluation framework.

resultsFourteen studies were finally included. Based on unadjusted data, NSBBs significantly increased the risk of developing renal dysfunction (OR = 1.49;

conclusionsNSBBs may not be associated with the development of renal dysfunction in liver cirrhosis. However, more evidence is required to clarify their association in specific populations.

Indexed as

End Stage Liver DiseaseKidney DiseasesAdrenergic beta-AntagonistsAscitesHumansLiver CirrhosisSeverity of Illness IndexAdrenergic beta-Antagonistsacute kidney injuryhepatorenal syndromeliver cirrhosisNonselective β blockerspropranolol

Identifiers

PMID38271554
PMCPMC10812853
OpenAlexW4391215224

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.